Physician profile
Mark J Moore
NPI 1962489567
$2,793.27
in general payments reported to CMS, 2019-2025
25 companies · $916 in 2025
The $916 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $662 · 2022: $188 · 2023: $592 · 2024: $435 · 2025: $916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,942.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $741.47 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $401.58 | 2021-2025 | Verquvo, Capvaxive |
| Medtronic, INC. | $271.49 | 2023-2025 | Micra, Symplicity G3, Reveal Linq |
| Pfizer INC. | $244.59 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $143.92 | 2023-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $139.26 | 2025 | Varithena Administration Pack |
| Amgen INC. | $123.54 | 2021-2023 | Repatha |
| Janssen Pharmaceuticals, INC | $113.05 | 2021 | |
| Lilly USA, LLC | $101.49 | 2025 | Zepbound |
| Astrazeneca Pharmaceuticals LP | $86.09 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $71.36 | 2025 | |
| Esperion Therapeutics, INC. | $43.91 | 2021-2025 | Nexletol |
| Novo Nordisk INC | $40.91 | 2021-2025 | Wegovy |
| Astellas Pharma US INC | $40.07 | 2021 | |
| Abbott Laboratories | $37.49 | 2021-2023 | Cardiomems |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $35.96 | 2023 | |
| Silk Road Medical, INC. | $27.90 | 2022 | |
| Alnylam Pharmaceuticals INC. | $19.94 | 2025 | Amvuttra |
| Cvrx, INC. | $18.53 | 2024 | Barostim Neo System |
| Kiniksa Pharmaceuticals International, Plc | $17.31 | 2024 | Arcalyst |
| Kowa Pharmaceuticals America, INC. | $16.16 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $15.09 | 2024 | Evkeeza |
| Itamar Medical INC | $14.89 | 2023 | Watchpatone |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.64 | 2023 | Jardiance |
| Glaxosmithkline, LLC. | $13.63 | 2025 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.